BACKGROUND The new strategies proposed for implementing the immune response elicited by influenza vaccines in the elderly, include using adjuvanted vaccine or intradermal vaccination route. The immunogenicity and the ability of preventing serologic determined influenza infections of an intradermal influenza vaccine was compared with that of an adjuvanted vaccine in the elderly. METHODS Eighty volunteers ( ≥ 65 years) were immunized with one dose of trivalent 2011/2012 influenza vaccine (A/Perth/16/09, H3N2; A/California/7/09, H1N1; B/Brisbane/60/08): either a split-virion vaccine containing 15mcg haemagglutinin(HA)/strain/0.1-ml dose administered intradermally (INTANZA, Sanofi-Pasteur) (n=40), or a subunit vaccine (15mcg HA/strain/0.5-ml dose) adjuvanted with MF59 and administered intramuscularly (FLUAD, Novartis) (n=40). Haemagglutination inhibiting antibodies titers were measured in blood specimens collected prior and one month after vaccination, and at the end of the influenza season for evaluation of immune response to vaccination and serologic determination of influenza infection. RESULTS Comparing the responses induced by the two vaccines (titers before and one month after vaccination) the results were similar against the A/H3N2 and A/H1N1 strains, whereas responses against the B strain were in general higher after INTANZA as compared with FLUAD. The criteria of the European Commission, were always satisfied, except for mean fold increase of titers and positive responses against B strain in people receiving FLUAD. Serological confirmed A/H3N2 influenza virus infection, i. e. seroconversions comparing sera collected 30 and 180 days after vaccination, were found in 11 volunteers, 5 vaccinated with FLUAD and 6 with INTANZA. CONCLUSIONS The responses induced by the 2011/2012 intradermal influenza vaccine compared with adjuvanted vaccine in the elderly were similar against A/H3N2 and A/H1N1 strains and higher against the B strain. A/H3N2 serologic determined infections were found both after intradermal and adjuvanted vaccines.
Antibody response and protection after intradermal and intramuscular 2011/2012 trivalent influenza vaccination in elderly volunteers
CAMILLONI, Barbara;BASILEO, Michela;LEPRI, Enrica;IORIO, Anna Maria
2012
Abstract
BACKGROUND The new strategies proposed for implementing the immune response elicited by influenza vaccines in the elderly, include using adjuvanted vaccine or intradermal vaccination route. The immunogenicity and the ability of preventing serologic determined influenza infections of an intradermal influenza vaccine was compared with that of an adjuvanted vaccine in the elderly. METHODS Eighty volunteers ( ≥ 65 years) were immunized with one dose of trivalent 2011/2012 influenza vaccine (A/Perth/16/09, H3N2; A/California/7/09, H1N1; B/Brisbane/60/08): either a split-virion vaccine containing 15mcg haemagglutinin(HA)/strain/0.1-ml dose administered intradermally (INTANZA, Sanofi-Pasteur) (n=40), or a subunit vaccine (15mcg HA/strain/0.5-ml dose) adjuvanted with MF59 and administered intramuscularly (FLUAD, Novartis) (n=40). Haemagglutination inhibiting antibodies titers were measured in blood specimens collected prior and one month after vaccination, and at the end of the influenza season for evaluation of immune response to vaccination and serologic determination of influenza infection. RESULTS Comparing the responses induced by the two vaccines (titers before and one month after vaccination) the results were similar against the A/H3N2 and A/H1N1 strains, whereas responses against the B strain were in general higher after INTANZA as compared with FLUAD. The criteria of the European Commission, were always satisfied, except for mean fold increase of titers and positive responses against B strain in people receiving FLUAD. Serological confirmed A/H3N2 influenza virus infection, i. e. seroconversions comparing sera collected 30 and 180 days after vaccination, were found in 11 volunteers, 5 vaccinated with FLUAD and 6 with INTANZA. CONCLUSIONS The responses induced by the 2011/2012 intradermal influenza vaccine compared with adjuvanted vaccine in the elderly were similar against A/H3N2 and A/H1N1 strains and higher against the B strain. A/H3N2 serologic determined infections were found both after intradermal and adjuvanted vaccines.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
